Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor
- PMID: 1998971
- PMCID: PMC11038957
- DOI: 10.1007/BF01789047
Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor
Abstract
The effect of cell-free ascitic fluid from patients with epithelial ovarian carcinoma on the generation of lymphokine-activated killer cells (LAK) was compared to the activity generated in control medium containing 10% fetal bovine serum, using Daudi target cells. Samples of ascitic fluid from nine different patients tested inhibited LAK generation. Suppressive activity was evident as early as 24 h of incubation in the presence of ascitic fluid and increasing suppression developed with prolonged exposure. Suppression was concentration-dependent, present at 10%-20% and increasing with concentrations up to 80%. The suppressive effect of ascitic fluid was only partially reversed on increasing the concentration of interleukin-2 (IL-2) from 10 units to 1000 units/ml. Activated LAK appeared to maintain the majority of their activity on further culture in ascitic fluid in the presence of IL-2 but further enhancement of lytic activity was prevented. Fractionation of a suppressive sample by HPLC, using 0.1 M KCl/acetic acid buffer pH 2.6, revealed that the dominant peak of suppressive activity eluted at 25 kDa; with pH 7.0 TRIS-buffered saline, most of the activity was lost on the column. Antibody neutralization studies of the 25-kDa suppressive peak as well as on whole ascitic fluid have revealed that transforming growth factor beta (TGF beta) is the major suppressive factor present in ascitic fluid. Factors that suppress LAK generation in vitro were present in all samples tested. The effect on the lytic activity of activated LAK cells was minimal. This suggests that, in the clinical setting, the greatest impact would be achieved by activating LAK cells ex vivo and subsequently transferring them to the peritoneal cavity in the presence of IL-2 rather than by attempting to generate them in situ by injecting IL-2 into the peritoneal cavity. However, reversal of TGF beta-mediated suppression in situ may be necessary to allow local proliferation of LAK cells to achieve an effective killer-to-target ratio.
Similar articles
-
Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-beta in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody.Cell Immunol. 1992 Jun;142(1):207-16. doi: 10.1016/0008-8749(92)90281-s. Cell Immunol. 1992. PMID: 1534038
-
Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.J Soc Gynecol Investig. 1995 Nov-Dec;2(6):762-71. J Soc Gynecol Investig. 1995. PMID: 9420887
-
Effector function of lymphokine-activated killer cells and cytotoxic T lymphocytes in ovarian epithelial carcinoma.Gynecol Oncol. 1990 Aug;38(2):191-6. doi: 10.1016/0090-8258(90)90039-n. Gynecol Oncol. 1990. PMID: 2387535
-
Evidence that interleukin-4 suppression of lymphokine-activated killer cell induction is mediated through monocytes.Immunology. 1992 Feb;75(2):343-8. Immunology. 1992. PMID: 1551696 Free PMC article.
-
[Effect of malignant ascitic fluids and OK-432 on the induction of LAK activity in peripheral blood mononuclear cells of gynecological cancer patients].Nihon Sanka Fujinka Gakkai Zasshi. 1991 Jun;43(6):611-8. Nihon Sanka Fujinka Gakkai Zasshi. 1991. PMID: 1856521 Japanese.
Cited by
-
Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor beta inhibition of lymphokine-activated killer cell generation.J Cancer Res Clin Oncol. 1993;119(3):131-6. doi: 10.1007/BF01229526. J Cancer Res Clin Oncol. 1993. PMID: 8380285 Free PMC article.
-
Transforming growth factor-beta synthesis by human peritoneal mesothelial cells. Induction by interleukin-1.Am J Pathol. 1996 May;148(5):1679-88. Am J Pathol. 1996. PMID: 8623935 Free PMC article.
-
Progression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlations.Cancer Immunol Immunother. 1994 Mar;38(3):160-6. doi: 10.1007/BF01525636. Cancer Immunol Immunother. 1994. PMID: 7907273 Free PMC article.
-
In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.Br J Cancer. 1995 Oct;72(4):928-33. doi: 10.1038/bjc.1995.435. Br J Cancer. 1995. PMID: 7547242 Free PMC article.
-
Oncolytic virotherapy for ovarian cancer.Oncolytic Virother. 2012 Aug;1:1-21. doi: 10.2147/ov.s31626. Oncolytic Virother. 2012. PMID: 25977900 Free PMC article.
References
-
- Badger AM, Oh SK, Moolten FR. Differential effects of an immunosuppressive fraction from ascites fluid of patients with ovarian cancer on spontaneous and antibody-dependent cytotoxicity. Cancer Res. 1981;41:1133. - PubMed
-
- Cianciolo GJ, Copeland TD, Oroszlan S, Snyderman R. Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science. 1985;230:453. - PubMed
-
- Cianciolo GJ, Snyderman R. Effects of tumor growth on host defenses. Cancer Metastasis Rev. 1986;5:15. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical